BNTX
BioNTech SEPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 24 ▲ BioNTech presented new clinical data from its late-stage lung cancer…
- Apr 11 ▲ BioNTech announced positive Phase 2 results for trastuzumab pamirtec…
- Apr 22 ▼ 1 insider sell $5.5M at $110.56
- Jun 30 ▲ 3 funds open new positions (13F)
- Sep 3 to Oct 9 ▼ 26 days of insider sells: $84.2M by 1 insider, avg $98.15
- Sep 8 ▼ BMO Capital downgrades
- Sep 14 ▲ BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in…
- Oct 12 Trial readout: Results Pending: BNT162b2 (2025/2026 formulation) (Phase 3…
- Oct 13 ▼ BioNTech announced that its Phase 2/3 AHEAD-MERIT trial for mRNA can…
- Oct 16 Trial readout: Results Pending: BNT162b2 Vaccine (Phase 3), Completed 24d…
- Oct 25 ▲ BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-1…
- Oct 26 ▼ BioNTech and DualityBiologics announced that the Phase 3 DYNASTY-Bre…
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $89.8M.
- InstitutionsBULLISH
Q2 2026: 30 added (3 new), 19 trimmed or exited. Largest new: Assenagon Asset Management S.A $39.4M, Point72 Asset Management, $30.4M.
- AnalystsBULLISH
20 of 29 rate it Buy or better.
- Short sellersSTEADY
Short interest −1.2% to 2.25M shares. 2.1 days to cover, ≈0.9% of shares.
- TrendDOWNTREND
8% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 9.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $704.6M |
| FLOSSBACH VON STORCH SE | TRIM | $207.1M |
| BAILLIE GIFFORD & CO | TRIM | $55.1M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $54.9M |
| BANK OF AMERICA CORP /DE/ | TRIM | $45.2M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | $43.1M |
| Assenagon Asset Management S.A. | NEW | $39.4M |
| D. E. Shaw & Co., Inc. | DOUBLED | $38.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
29 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 4, 2026 | UBS MAINTAIN | Buy |
| Nov 4, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 4, 2026 | Wells Fargo MAINTAIN | Overweight |
| Nov 4, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Oct 14, 2026 | Canaccord Genuity MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sahin Ugur Chief Executive Officer Oct 9, 2026 | SELL | $3.5M |
Sahin Ugur Chief Executive Officer Oct 8, 2026 | SELL | $2.5M |
Sahin Ugur Chief Executive Officer Oct 7, 2026 | SELL | $2.3M |
Sahin Ugur Chief Executive Officer Oct 6, 2026 | SELL | $2.0M |
Sahin Ugur Chief Executive Officer Oct 5, 2026 | SELL | $7.0M |
Sahin Ugur Chief Executive Officer Oct 2, 2026 | SELL | $1.6M |
Sahin Ugur Chief Executive Officer Oct 1, 2026 | SELL | $1.7M |
Sahin Ugur Chief Executive Officer Sep 30, 2026 | SELL | $3.1M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$1.89 | -$1.89–-$1.89 | -11.2% | $153.6M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
26 filings · 12 press releases · 4 bullish · 5 bearish · 4 mixed · 13 neutral- NEUTRAL 6-KNov 10, 2026
BioNTech announced it will acquire an FDA Priority Review Voucher from Scholar Rock for $205…
The acquisition signals BioNTech's intent to file a late-stage oncology asset for FDA approval in the near-to-medium term. Monitor for which specific pipeline candidate will use the voucher and for…
- NEUTRAL 6-KNov 3, 2026
BioNTech reported Q3 2026 revenue of €1,289.2M, down 15% YoY from €1,518.9M, driven by a 35%…
The Q3 beat was driven by a one-time €70M milestone and the timing of out-licensing revenue recognition, not by core operating improvement. COVID-19 vaccine revenue continues to decline…
- NEUTRAL 6-KNov 3, 2026
BioNTech reported Q3 2026 revenue of 1,289.2 million (down 15% YoY from 1,518.9 million) and IFRS…
Revenue beat consensus and guidance midpoint raised, but the underlying trend is declining COVID-19 vaccine revenue as the company transitions to oncology. Key catalysts to watch: the first interim…
- NEUTRAL PRESS-RELEASENov 3, 2026
BioNTech reported Q3 2026 revenue of €1,289.2M, beating the €1,040M consensus, and GAAP diluted…
Revenue beat and raised guidance are positive, but EPS miss and mixed pipeline data (trastuzumab pamirtecan modest PFS benefit with ILD risk, BNT113 PFS failure) temper enthusiasm. Watch for OS…
All BNTX filing & press-release reports (38)
- 6-K reportNov 10, 2026
- 6-K reportNov 3, 2026
- 6-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- INST-CLUSTER reportOct 29, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 26, 2026
- PRESS-RELEASE reportOct 26, 2026
- PRESS-RELEASE reportOct 25, 2026
- 6-K reportOct 22, 2026
- 6-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- 6-K reportOct 13, 2026
- 6-K reportSep 14, 2026
- PRESS-RELEASE reportSep 14, 2026
- 6-K reportAug 28, 2026
- 6-K reportAug 20, 2026
- INST-CLUSTER reportAug 11, 2026
- 6-K reportAug 4, 2026
- 6-K reportAug 3, 2026
- PRESS-RELEASE reportAug 3, 2026
- 6-K reportJul 29, 2026
- 6-K reportJun 8, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportMay 30, 2026
- 6-K reportMay 22, 2026
- PRESS-RELEASE reportMay 22, 2026
- 6-K reportMay 15, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 5, 2026
- 6-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportApr 21, 2026
- 6-K reportApr 13, 2026
- PRESS-RELEASE reportApr 11, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 10, 2026